SOPHiA GENETICS (NASDAQ:SOPH) PT Lowered to $7.00

SOPHiA GENETICS (NASDAQ:SOPH) had its target price dropped by stock analysts at Royal Bank of Canada from $8.00 to $7.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 86.67% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Guggenheim initiated coverage on SOPHiA GENETICS in a research report on Thursday, June 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Morgan Stanley downgraded shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $10.00 to $5.00 in a report on Wednesday.

SOPHiA GENETICS Trading Down 7.6 %

Shares of SOPH traded down $0.31 on Wednesday, reaching $3.75. 56,533 shares of the company’s stock traded hands, compared to its average volume of 77,962. The stock’s 50 day simple moving average is $4.71 and its two-hundred day simple moving average is $4.78. SOPHiA GENETICS has a 52-week low of $2.13 and a 52-week high of $7.37. The stock has a market cap of $245.18 million, a PE ratio of -3.42 and a beta of 1.06.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. The company had revenue of $15.81 million during the quarter, compared to analyst estimates of $17.58 million. SOPHiA GENETICS had a negative return on equity of 47.56% and a negative net margin of 113.71%. During the same quarter last year, the company earned ($0.33) earnings per share. Analysts forecast that SOPHiA GENETICS will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its position in SOPHiA GENETICS by 35.9% in the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after acquiring an additional 361,201 shares in the last quarter. Akre Capital Management LLC purchased a new stake in SOPHiA GENETICS during the first quarter worth approximately $1,418,000. Essex Investment Management Co. LLC increased its position in shares of SOPHiA GENETICS by 112.1% in the first quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock worth $1,296,000 after acquiring an additional 138,933 shares in the last quarter. Moloney Securities Asset Management LLC raised its stake in shares of SOPHiA GENETICS by 111.4% in the 1st quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after acquiring an additional 93,800 shares during the period. Finally, Edmond DE Rothschild Holding S.A. increased its holdings in SOPHiA GENETICS by 5.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock valued at $1,002,000 after purchasing an additional 9,700 shares in the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.